{{Rsnum
|rsid=35599367
|Gene=CYP3A4
|Chromosome=7
|position=99768693
|Orientation=minus
|GMAF=0.02158
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP3A4
}}{{PMID Auto
|PMID=20386561
|Title=Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
|OA=1
}}
{{PMID Auto
|PMID=21903774
|Title=A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
}}
{{PMID Auto
|PMID=21902502
|Title=Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients
}}{{PMID Auto
|PMID=21946898
|Title=Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
}}

{{PMID Auto
|PMID=22388796
|Title=The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.
}}
{{PMID Auto
|PMID=23252948
|Title=CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
}}
{{PMID Auto
|PMID=23574377
|Title=Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms
}}{{PMID Auto
|PMID=23501331
|Title=Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
}}